

Supplementary Table 1. Results of secondary endpoints

Variable	LS mean \pm SE from baseline		LS mean difference between groups (95% CI)	P value
	Placebo (n=141)	Evogliptin (n=140)	Evogliptin-Placebo	
SBP, mm Hg				
Change from baseline at week 24	-0.17 \pm 0.93	0.24 \pm 0.92	0.41 \pm 1.29 (-2.14 to 2.96)	0.7496
Change from baseline at week 52	0.88 \pm 1.06	0.24 \pm 1.03	-0.63 \pm 1.47 (-3.52 to 2.25)	0.6657
DBP, mm Hg				
Change from baseline at week 24	0.54 \pm 0.69	-0.22 \pm 0.68	-0.76 \pm 0.96 (-2.64 to 1.13)	0.4292
Change from baseline at week 52	-0.94 \pm 0.85	-1.12 \pm 0.82	-0.18 \pm 1.17 (-2.49 to 2.13)	0.8760
Total cholesterol, mg/dL				
Change from baseline at week 24	5.32 \pm 2.49 ^a	2.19 \pm 2.48	-3.14 \pm 3.47 (-9.96 to 3.69)	0.3662
Change from baseline at week 52	5.93 \pm 2.49 ^a	2.55 \pm 2.38	-3.38 \pm 3.39 (-10.05 to 3.28)	0.3184
LDL-C, mg/dL				
Change from baseline at week 24	1.72 \pm 2.00	1.54 \pm 2.00	-0.17 \pm 2.79 (-2.53 to 0.77)	0.9502
Change from baseline at week 52	1.03 \pm 2.16	-0.18 \pm 2.06	-1.21 \pm 2.95 (-7.02 to 4.60)	0.6826
HDL-C, mg/dL				
Change from baseline at week 24	2.02 \pm 0.60 ^b	1.14 \pm 0.60	-0.88 \pm 0.84 (-2.53 to 0.77)	0.2954
Change from baseline at week 52	1.81 \pm 0.62 ^b	-0.37 \pm 0.58	-2.18 \pm 0.84 (-3.83 to -0.53)	0.0097 ^b
Triglyceride, mg/dL				
Change from baseline at week 24	8.40 \pm 10.14	-7.21 \pm 10.12	-15.61 \pm 14.12 (-43.40 to 12.18)	0.2697
Change from baseline at week 52	-6.13 \pm 7.26	10.55 \pm 6.73	16.69 \pm 9.60 (-2.20 to 35.58)	0.0832
Free fatty acids, mg/dL				
Change from baseline at week 24	0.12 \pm 19.59	-31.03 \pm 19.54	-31.15 \pm 27.27 (-84.85 to 22.54)	0.2544
Change from baseline at week 52	-13.95 \pm 21.75	-43.33 \pm 20.09 ^a	-29.38 \pm 29.12 (-86.72 to 27.96)	0.3140
Body weight, kg				
Change from baseline at week 24	-0.62 \pm 0.20 ^b	-0.03 \pm 0.20	0.59 \pm 0.28 (0.05 to 1.13)	0.0330 ^a
Change from baseline at week 52	-0.88 \pm 0.26 ^b	-0.30 \pm 0.24	0.57 \pm 0.35 (-0.12 to 1.27)	0.1067
HOMA-IR				
Change from baseline at week 24	-0.03 \pm 0.14	-0.22 \pm 0.14	-0.19 \pm 0.20 (-0.58 to 0.21)	0.3498
Change from baseline at week 52	-0.11 \pm 0.18	-0.03 \pm 0.17	0.07 \pm 0.25 (-0.42 to 0.56)	0.7736
QUICKI				
Change from baseline at week 24	0.00 \pm 0.00	0.00 \pm 0.00	0.00 \pm 0.00 (-0.00 to 0.01)	0.3578
Change from baseline at week 52	0.00 \pm 0.00	-0.00 \pm 0.00	-0.00 \pm 0.00 (-0.01 to 0.00)	0.2565
Glucagon				
Change from baseline at week 24	-0.76 \pm 0.29	-0.50 \pm 0.29	0.26 \pm 0.40 (-0.52 to 1.04)	0.5122
Change from baseline at week 52	-0.76 \pm 0.40	-0.36 \pm 0.39	0.39 \pm 0.55 (-0.70 to 1.48)	0.4775

Testing for the difference between treatment groups (the mixed effect model repeated measure analysis).

LS, least square; SE, standard error; CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment of insulin resistance; QUICKI, quantitative insulin sensitivity check index.

^aP<0.05, ^bP<0.01.